Menu
Avian Influenza (Bird Flu): H5N1
Only FDA Rapid Test
FDA Approved (510(k)-cleared)
Influenza, an RNA virus, has the ability to genetically reassort, specifically by antigenic shift, and can therefore mutate into a form that compromises vaccine effectiveness and to which a naive population has no immunity.
Avian influenza H7N9 is one example which emerged in March 2013 in China, reappearing again in January 2014. Most had contact with live bird markets, but human-to-human transmission is also suspected. Although it has killed fewer than 200 people, it has a mortality rate of 30%.
Fast and early diagnosis plays an important role in detection and containment of influenza pandemics. In conjunction with the United States Navy,
Arbor Vita has developed rapid tests against A/H5N1 and A/H7N9 that could, unlike more equipment-intensive and complicated PCR tests, be used in such critical entry points as airports.
One of only two tests approved by the FDA for specific testing, ensuring reliability and compliance with regulatory standards.
Approved for use in all High Complexity CLIA-certified laboratories, ensuring compliance with stringent testing standards.
Tested and validated by RADx, the NIH Taskforce for Pandemic Testing, ensuring accuracy and reliability in critical health situations.
Results available in less than 1 hour, ensuring fast, reliable, and efficient testing for timely decision-making in critical settings.
As COVID-19 continues to prove itself a persistent global threat, Arbor Vita now offers direct COVID-19 testing for individuals and healthcare providers. In addition to our own in-house technology, we are continually seeking the best COVID-19 tests available to offer our customers, including detection of the new Delta/India subtype.
In this regard, Arbor Vita has collaborated with Yale University to bring you the SalivaDirect™ SARS-CoV-2 test. This FDA EUA-authorized test combines accurate, industry-standard RT-PCR technology with painless saliva sample collection.
All of our tests include SAME DAY RESULTS if your sample is received by 11am! Come learn about our CLIA-certified facilities and order your test today.
Arbor Vita Corporation's advances in proteomic diagnostics mean the presence of cancer can now be detected rapidly and in the earliest, most treatable stages
Our testing technologies will radically improve the health outcomes of the over 2 billion women worldwide who are at risk for cervical cancer
Arbor Vita Corporation is devoted to protecting the health of women of all ages, races, and geographic locations. Current screening methods, such as the Pap smear and HPV DNA tests, detect cervical cell changes or the presence of (often harmless) HPV, but require a sophisticated processing protocol, limiting their efficacy and applicability—especially in rural areas. By contrast, the OncoE6™ Cervical Test can be used in both advanced settings and ones with limited infrastructure. It requires no refrigeration, is easy to administer (even via self-collection), and yields results in just over two hours. What’s more, our test can capture the same urgent, accurate results for women under 21 and over 60 who have been marginalized by conventional testing.
Over 250 PDZ domain-containing proteins have been described in the human proteome. Irregular cell activation contributes to malignancies; PDZ proteins therefor comprise a new class of functional drug targets and diagnostic markers. We have a near-complete library of PDZ domains and have identified new interaction inhibitors, which will fuel the development of diagnostics and therapeutics.
Arbor Vita Corporation has unique capabilities in developing and manufacturing high- quality monoclonal antibodies (mAbs). This has enabled us to create a valuable and large library for the detection of select low-risk and all high-risk HPV oncoprotein E6/E7 types, specific influenza subtypes, as well as a variety of other proteins in infectious diseases and cancers.
Using PDZ domains and monoclonal antibodies, we have developed a pipeline of highly sensitive tests that can be used at the time and site of patient contact to detect specific disease protein markers. These tests (such as the OncoE6™ Cervical Test and the avian influenza detection tests), provide quick, actionable results and can be used in both advanced and remote healthcare settings.
Address: 48371 Fremont Blvd, Suite 101
Fremont, CA 94538
HOURS
SUN: CLOSED
MON: 8AM-5PM
TUE: 8AM-5PM
WED: 8AM-5PM
THU: 8AM-5PM
FRI: 8AM-5PM
SAT: 9AM-12N
OTHER TIMES, PLEASE INQUIRE
